“
TL;DR
The authors hypothesize the enteric coating compound methacrylic acid, present in his medication, may be a contributing factor.
JPGN Reports · 4 authors, 4 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The authors hypothesize the enteric coating compound methacrylic acid, present in his medication, may be a contributing factor.
This is a single-patient case report of a 6-year-old male with cystinosis and stage 2 chronic kidney disease, treated with delayed-release cysteamine bitartrate (Procysbi). He presented with new-onset bloody stool and abdominal pain, with a history of chronic gastrointestinal symptoms. Colonoscopy revealed colonic erythema and cobblestoning, and an iatrogenic perforation occurred during the procedure. Surgical exploration found a thickened, stenotic ascending colon and distal ileal dilation, consistent with high-grade obstruction, and pathology confirmed fibrosing colonopathy. They raise the question of a possible causal association, suggesting morbidity could evolve in patients taking medications formulated with methacrylic acid. Limitations include the single-case nature, which precludes establishing causality, and the unexplained pathophysiology of the drug association.